Summary: It has been well known for a long period of time, that patients with congenital or acquired states of immunodeficiency have an increased incidence of malignant lymphomas. This observation is gaining more clinical interest and importance in connectior with the increasing incidence of malignant lymphomas in HIV positive patients. This paper reviews the epidemiology, etiology, pathology, clinical picture and treatment of malignant lymphomas in the immunocompromised patient (MLICP).
Because of the potential complications and impairment of the underlying immunodeficiency diseases, highly aggressive, dose intensity chemotherapy regimen do not appear to be of any adantage in the treatment of this disease. Specific recommendations for the clinical management of MLICP in Czechoslovakia are made, which include the referral of these p tients to selected institutions with high quality supportive care and the development of clinical research study protocols for their treatment.
Malignant lymphomas in patiens with immunity defect
